World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders
暂无分享,去创建一个
D. Rujescu | E. Hollander | N. Fineberg | S. Kasper | D. Stein | S. Tsai | K. Domschke | D. Denys | V. Starcevic | J. Zohar | S. Pallanti | D. Baldwin | J. Hättenschwiler | C. Allgulander | A. Nardi | Zhen Wang | G. Perna | E. Miguel | B. Bandelow | Yong-Ku Kim | Daniel L. C. Costa | E. Eriksson | H. Kaiya | V. Masdrakis | M. Van Ameringen | M. Katzman | N. Dilbaz | A. Vasileva | T. Karavaeva | J. M. Menchón | L. Lim | Takeshi Inoue | H. Möller | Giampaolo Robert Perna | J. Menchón
[1] D. Wedekind,et al. Internet psychotherapeutic interventions for anxiety disorders – a critical evaluation , 2022, BMC Psychiatry.
[2] M. Beutel,et al. The German Guidelines for the treatment of anxiety disorders: first revision , 2021, European Archives of Psychiatry and Clinical Neuroscience.
[3] D. Baldwin. Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications. , 2021, Addiction.
[4] D. Baldwin,et al. Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively , 2021, CNS Drugs.
[5] B. Bandelow. The myth that psychotherapy is more effective than pharmacotherapy in anxiety disorders , 2021, European Neuropsychopharmacology.
[6] R. Shader,et al. Benzodiazepines: it's time to return to the evidence , 2020, The British Journal of Psychiatry.
[7] Alyssa M. Peckham,et al. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update , 2020, Drugs.
[8] Marian Buhociu,et al. Not what the doctor ordered: Motivations for nonmedical prescription drug use among people who use illegal drugs. , 2020, The International journal on drug policy.
[9] D. Caldirola,et al. Relapse prevention in panic disorder with pharmacotherapy: where are we now? , 2020, Expert opinion on pharmacotherapy.
[10] K. Domschke,et al. A neurobiological framework of separation anxiety and related phenotypes , 2020, European Neuropsychopharmacology.
[11] S. Kellett,et al. The dose-response effect in routinely delivered psychological therapies: A systematic review , 2020, Psychotherapy research : journal of the Society for Psychotherapy Research.
[12] N. Dreyer,et al. Trial designs using real‐world data: The changing landscape of the regulatory approval process , 2019, Pharmacoepidemiology and drug safety.
[13] N. Singewald,et al. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. , 2019, Pharmacology & therapeutics.
[14] Kuan-Chia Lin,et al. Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. , 2019, Journal of psychiatric research.
[15] R. Blashfield,et al. Anxiety in Children with Selective Mutism: A Meta-analysis , 2019, Child Psychiatry & Human Development.
[16] J. Krystal,et al. Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment , 2019, Journal of psychopharmacology.
[17] M. Mula,et al. Treatment of psychoses in patients with epilepsy: an update , 2019, Therapeutic advances in psychopharmacology.
[18] Mean age and gender distribution of patients with major mental disorders participating in clinical trials , 2019, European Archives of Psychiatry and Clinical Neuroscience.
[19] H. Möller,et al. WFSBP guidelines on how to grade treatment evidence for clinical guideline development , 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[20] W. Rief,et al. It can’t hurt, right? Adverse effects of psychotherapy in patients with depression , 2018, European Archives of Psychiatry and Clinical Neuroscience.
[21] P. Cuijpers,et al. Efficacy and acceptability of psychological interventions for social anxiety disorder in children and adolescents: a meta-analysis of randomized controlled trials , 2018, European Child & Adolescent Psychiatry.
[22] J. Kornhuber,et al. Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis , 2018, JAMA psychiatry.
[23] S. Hofmann,et al. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review , 2018, Expert opinion on pharmacotherapy.
[24] D. Wedekind,et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies , 2018, The British Journal of Psychiatry.
[25] R. Kessler,et al. Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries , 2018, Depression and anxiety.
[26] E. Foa,et al. Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial , 2018, JAMA.
[27] F. Schneier,et al. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder , 2017, Depression and anxiety.
[28] A. Young,et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017 , 2017, Journal of psychopharmacology.
[29] D. Nutt,et al. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[30] F. Verhulst,et al. The Age of Onset of Anxiety Disorders , 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[31] M. Lapeyre-Mestre,et al. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. , 2016, Therapie.
[32] S. Tsai,et al. Treatment-resistant panic disorder: clinical significance, concept and management , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[33] M. Bloch,et al. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.
[34] D. Nutt,et al. Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics , 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[35] P. Salkovskis,et al. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. , 2016, Health technology assessment.
[36] H. Simpson,et al. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive‐compulsive disorder , 2016, World psychiatry : official journal of the World Psychiatric Association.
[37] K. Manassis,et al. The use of medication in selective mutism: a systematic review , 2016, European Child & Adolescent Psychiatry.
[38] S. Hollon,et al. Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials , 2015, PloS one.
[39] W. Naja,et al. Pregabalin dependence: a case report. , 2015, Current drug safety.
[40] P. Cuijpers,et al. Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta‐analysis , 2015, World psychiatry : official journal of the World Psychiatric Association.
[41] Gavin Andrews,et al. Treatment-as-usual (TAU) is anything but usual: a meta-analysis of CBT versus TAU for anxiety and depression. , 2015, Journal of affective disorders.
[42] D M Caldwell,et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta‐analysis , 2014, Acta psychiatrica Scandinavica.
[43] D. Kupfer,et al. A proposal for an updated neuropsychopharmacological nomenclature , 2014, European Neuropsychopharmacology.
[44] A. Ehlers,et al. A randomized controlled trial of 7-day intensive and standard weekly cognitive therapy for PTSD and emotion-focused supportive therapy. , 2014, The American journal of psychiatry.
[45] C. Dennis,et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis , 2014, BMJ : British Medical Journal.
[46] M. Stein,et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. , 2014, The American journal of psychiatry.
[47] R. Shavitt,et al. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. , 2013, Journal of psychiatric research.
[48] Christopher W. Jones,et al. Non-publication of large randomized clinical trials: cross sectional analysis , 2013, BMJ.
[49] C. Cooper,et al. The relationship between depression, anxiety and cardiovascular disease: findings from the Hertfordshire Cohort Study. , 2013, Journal of affective disorders.
[50] J. Hilden,et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors , 2013, Canadian Medical Association Journal.
[51] C. Schönfeldt-Lecuona,et al. Pregabalin abuse and dependence in Germany: results from a database query , 2013, European Journal of Clinical Pharmacology.
[52] R. Kessler,et al. Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States , 2012, International journal of methods in psychiatric research.
[53] J. Olesen,et al. The economic cost of brain disorders in Europe , 2012, European journal of neurology.
[54] R. Dishman,et al. Feasibility of Exercise Training for the Short-Term Treatment of Generalized Anxiety Disorder: A Randomized Controlled Trial , 2011, Psychotherapy and Psychosomatics.
[55] Anders Sundström,et al. A signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting system , 2010, European Journal of Clinical Pharmacology.
[56] Dan J Stein,et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database , 2009, Human psychopharmacology.
[57] J. Carlson,et al. Efficacy of cognitive‐behavioral and pharmacological treatments for children with social anxiety , 2008, Depression and anxiety.
[58] Jean-Philippe Laurenceau,et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men the unique contribution of anxiety among psychologic factors. , 2008, Journal of the American College of Cardiology.
[59] D. Nutt,et al. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy , 2008, Journal of psychopharmacology.
[60] Hans-Jürgen Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[61] N. Frasure-smith,et al. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. , 2008, Archives of general psychiatry.
[62] J. Mann,et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. , 2007, The American journal of psychiatry.
[63] Dan J Stein,et al. Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo , 2007, Pharmacopsychiatry.
[64] G. Rubio,et al. Generalized anxiety disorder: a 40‐year follow‐up study , 2007, Acta psychiatrica Scandinavica.
[65] P. Mbaya,et al. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder , 2007, Human psychopharmacology.
[66] J. López-Ibor,et al. What can be learnt from the natural history of anxiety disorders? , 2007, European Psychiatry.
[67] J. Rogers,et al. Psychiatric comorbidity following traumatic brain injury , 2007, Brain injury.
[68] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia , 2006, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[69] A. Prange,et al. Psychiatric Manifestations of Graves’ Hyperthyroidism , 2006, CNS drugs.
[70] J. Hellings,et al. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents , 2006, Clinical drug investigation.
[71] J. Savarino,et al. Suicide risk during antidepressant treatment. , 2006, The American journal of psychiatry.
[72] H. Wittchen,et al. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies , 2005, European Neuropsychopharmacology.
[73] Olga V. Demler,et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.
[74] Olga V. Demler,et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.
[75] L. Scahill,et al. The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. , 2005, Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc.
[76] D. Nutt. Death by tricyclic: the real antidepressant scandal? , 2005, Journal of psychopharmacology.
[77] J. Januzzi,et al. The High Prevalence of Multiple Psychiatric Disorders in Stable Outpatients With Coronary Heart Disease , 2004, Psychosomatic medicine.
[78] Maria G. Tanzi,et al. Paradoxical Reactions to Benzodiazepines: Literature Review and Treatment Options , 2004, Pharmacotherapy.
[79] J. Lépine,et al. The European Study of the Epidemiology of Mental Disorders (ESEMeD) project: an epidemiological basis for informing mental health policies in Europe , 2004, Acta psychiatrica Scandinavica. Supplementum.
[80] F. Mazzi,et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.
[81] D. Nutt,et al. Treatment of anxiety and depressive disorders in patients with cardiovascular disease , 2004, BMJ : British Medical Journal.
[82] C. Pisinger,et al. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). A review , 2004, Nordic journal of psychiatry.
[83] N. Simon,et al. Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder , 2003, Journal of psychopharmacology.
[84] S. Čavaljuga,et al. Clomipramine and fluoxetine effects in the treatment of panic disorder. , 2003, Bosnian journal of basic medical sciences.
[85] M. Otto,et al. Treating Medication-Resistant Panic Disorder: Predictors and Outcome of Cognitive-Behavior Therapy in a Brazilian Public Hospital , 2002, Psychotherapy and Psychosomatics.
[86] R. Califf,et al. Sertraline treatment of major depression in patients with acute MI or unstable angina , 2002, European Neuropsychopharmacology.
[87] Dan J Stein,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[88] R A Gould,et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. , 2001, The American journal of psychiatry.
[89] E. Rüther,et al. Separation Anxiety and Actual Separation Experiences during Childhood in Patients with Panic Disorder , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[90] S. Woods,et al. Early coadministration of clonazepam with sertraline for panic disorder. , 2001, Archives of general psychiatry.
[91] E. Smeraldi,et al. A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study , 2001, Pharmacopsychiatry.
[92] D. A. Spiegel. Psychological strategies for discontinuing benzodiazepine treatment. , 1999, Journal of clinical psychopharmacology.
[93] J. Carlson,et al. Sertraline treatment of 5 children diagnosed with selective mutism: a single-case research trial. , 1999, Journal of child and adolescent psychopharmacology.
[94] U. Lepola,et al. The effect of Citalopram in panic disorder , 1997, British Journal of Psychiatry.
[95] Y. Lecrubier,et al. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder , 1997 .
[96] C. Gillberg,et al. Selective mutism: a population-based study: a research note. , 1997, Journal of child psychology and psychiatry, and allied disciplines.
[97] R. Daroff,et al. Clinical Handbook of Psychotropic Drugs , 1994 .
[98] E. Sellers,et al. Clinical aspects of chronic use of alprazolam and lorazepam. , 1995, The American journal of psychiatry.
[99] W. Boyer. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta‐analysis , 1995, International clinical psychopharmacology.
[100] B Black,et al. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.
[101] A. Bystritsky,et al. Double-blind pilot trial of desipramine versus fluoxetine in panic patients. , 1994, Anxiety.
[102] J. Rosenbaum,et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. , 1993, The American journal of psychiatry.
[103] J. Rosenbaum,et al. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. , 1993, Journal of clinical psychopharmacology.
[104] F. Goodwin,et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. , 1993, Archives of general psychiatry.
[105] M. Mavissakalian,et al. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. , 1992, Archives of general psychiatry.
[106] G. Klerman,et al. Drug Treatment of Panic Disorder: Comparative Efficacy of Alprazolam, Imipramine, and Placebo , 1992, British Journal of Psychiatry.
[107] S. Woods,et al. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. , 1992, Journal of clinical psychopharmacology.
[108] H. Koplewicz,et al. Imipramine treatment of children with separation anxiety disorder. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.
[109] P. Bech,et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study , 1991, Acta psychiatrica Scandinavica. Supplementum.
[110] D. Greenblatt,et al. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. , 1990, Archives of general psychiatry.
[111] P. Riekkinen,et al. Clinical evaluation of alprazolam in patients with panic disorder: A double‐blind comparison with imipramine , 1990 .
[112] W. Agras,et al. Cardiovascular and Symptomatic Reduction Effects of Alprazolam and Imipramine in Patients with Panic Disorder: Results of a Double-Blind, Placebo-Controlled Trial , 1990, Journal of clinical psychopharmacology.
[113] R. Glass,et al. Response of panic disorder to fixed doses of alprazolam or imipramine. , 1989, Journal of affective disorders.
[114] W. Goodman,et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. , 1989, Archives of general psychiatry.
[115] S. Woods,et al. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. , 1989, Archives of general psychiatry.
[116] T. Silverstone,et al. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with fluvoxamine and maprotiline. , 1988 .
[117] K. Rickels. Benzodiazepines in the treatment of anxiety. , 1982, American journal of psychotherapy.
[118] Jacob Cohen,et al. The statistical power of abnormal-social psychological research: a review. , 1962, Journal of abnormal and social psychology.
[119] M. Hamilton. The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.